Brief: Assembly Biosciences Doses First Participant In Phase 1B Clinical Trial Testing Abi-4334 For The Treatment Of Chronic Hepatitis B Virus Infection
18/06/2024 13:10
June 18 (Reuters) - Assembly Biosciences Inc ASMB.O :
* ASSEMBLY BIOSCIENCES DOSES FIRST PARTICIPANT IN PHASE 1B
CLINICAL TRIAL EVALUATING NEXT-GENERATION CAPSID ASSEMBLY
MODULATOR CANDIDATE ABI-4334 FOR THE TREATMENT OF CHRONIC
HEPATITIS B VIRUS INFECTION
Source text for Eikon: ID:nGNX5PK1zV
Further company coverage: ASMB.O
((Reuters.Briefs@thomsonreuters.com;))